The BATTLE trial: personalizing therapy for lung cancer.

  title={The BATTLE trial: personalizing therapy for lung cancer.},
  author={Edward S. Kim and Roy S. Herbst and Ignacio Wistuba and J Jack Lee and George R. Blumenschein and Anne S. Tsao and David J. Stewart and Marshall E. Hicks and Jeremy J. Erasmus and Sanjay Gupta and Christine M Alden and Suyu Liu and Ximing Tang and Fadlo R. Khuri and Hai T. Tran and Bruce Evan Johnson and John V. Heymach and Li Mao and Frank V. Fossella and Merrill S. Kies and Vassiliki A. Papadimitrakopoulou and Suzanne E. Davis and Scott Michael Lippman and Waun Ki Hong},
  journal={Cancer discovery},
  volume={1 1},
UNLABELLED The Biomarker-integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) trial represents the first completed prospective, biopsy-mandated, biomarker-based, adaptively randomized study in 255 pretreated lung cancer patients. Following an initial equal randomization period, chemorefractory non-small cell lung cancer (NSCLC) patients were adaptively randomized to erlotinib, vandetanib, erlotinib plus bexarotene, or sorafenib, based on relevant molecular biomarkers… CONTINUE READING
Highly Influential
This paper has highly influenced 18 other papers. REVIEW HIGHLY INFLUENTIAL CITATIONS
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
Blog posts, news articles and tweet counts and IDs sourced by